Abstract:Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune cells against microbial infection. Based on the finding that neutrophils can either restrict or promote cancer progression, tumor-associated neutrophils (TAN) are classified into anti-tumor N1 and pro-tumor N2 subsets. One of the major mechanisms underlying the tumor-promoting function of N2-TANs is suppression of adaptive immune cells, in particular, cytotoxic T lymphocytes. Currently, no established methodologies are available that can unequivocally distinguish immunosuppressive TANs and granulocytic/polymorphonuclear myeloid-derived suppressor cells (G/PMN-MDSC). In view of the critical role of PMN-MDSCs in immune evasion and resistance to cancer immunotherapy, as established from data obtained with diverse cancer models, therapeutic strategies targeting these cells have been actively developed to enhance the efficacy of immunotherapy. Here, we have reviewed the available literature on strategies targeting PMN-MDSCs and summarized the findings into four categories: (1) depletion of existing PMN-MDSCs, (2) blockade of the development of PMN-MDSCs, (3) blockade of PMN-MDSC recruitment, (4) inhibition of immunosuppressive function. Owing to their high mobility to inflamed organs and ability to trespass the blood-brain barrier, neutrophils are outstanding candidate carriers in nanoparticle-based therapies. Another attractive application of neutrophils in cancer therapy is the use of neutrophil membrane-derived nanovesicles as a surrogate of extracellular vesicles for more efficient and scalable drug delivery. In the second part of the review, we have highlighted recent advances in the field of neutrophil-based cancer drug delivery. Overall, we believe that neutrophil-based therapeutics are a rapidly growing area of cancer therapy with significant potential benefits.

Progress in Functions and Mechanisms of Immunosuppressive Neutrophil Subsets: an Update

Rational targeting of immunosuppressive neutrophils in cancer

Understanding the Multifaceted Role of Neutrophils in Cancer and Autoimmune Diseases

Targeting and Exploitation of Tumor-Associated Neutrophils to Enhance Immunotherapy and Drug Delivery for Cancer Treatment

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis

Neutrophils in the tumor microenvironment: role in tumor progression and potential targeted therapeutic strategy

Research progress of tumor associated neutrophils and their tumor promoting effects

Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies

Neutrophil: A New Player in Metastatic Cancers

The regulatory roles of neutrophils in adaptive immunity

A Variety of Death Modes of Neutrophils and Their Role in the Etiology of Autoimmune Diseases

Neutrophil diversity and plasticity: Implications for organ transplantation

Role of Neutrophils on Cancer Cells and Other Immune Cells in the Tumor Microenvironment

Neutrophils and PMN-MDSC: Their Biological Role and Interaction with Stromal Cells.

The Role of Cytokines in Neutrophil Development, Tissue Homing, Function and Plasticity in Health and Disease

Research progress in mechanisms of tumor-associated neutrophils promoting tumor metastasis

The emerging role of neutrophils in autoimmune‐associated disorders: effector, predictor, and therapeutic targets

Neutrophil diversity and plasticity in tumour progression and therapy

Neutrophils' dual role in cancer: from tumor progression to immunotherapeutic potential

Advanced Role Of Neutrophils In Common Respiratory Diseases

The Double-Edged Role of Neutrophil Heterogeneity in Inflammatory Diseases and Cancers.